Bloomberg’s Madison Muller joins Dani Burger on “Bloomberg Deals.” Eli Lilly agreed to buy closely held Calytrix Bio in a deal that could be worth up to $1.5 billion, the latest in the drugmaker’s $32 billion wave of acquisitions in 2026 as it builds out its cancer and immunology businesses. (Source: Bloomberg)
Results for “prostate cancer”
The U.S. regulator’s disclosure was more extensive than what the biotech company had announced Sunday.
Sellas Life Sciences Group Inc. surged after the drug developer reported positive late-stage trial results for an experimental cancer vaccine to treat an aggressive form of blood cancer.
Eli Lilly & Co. agreed to buy closely held Calytrix Bio Inc. in a deal that could be worth up to $1.5 billion, the latest in the drugmaker’s $32 billion wave of acquisitions in 2026 as it builds out its cancer and immunology businesses. Sam Fazeli, Bloomberg Intelligence, Director of Research for Global Industries and Senior Pharmaceuticals Analyst, discusses the biotech sector, how AI is playing a role in new developments and the importance of M&A through deals like that of Eli Lilly and Calytrix Bio. (Source: Bloomberg)
The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.
Britain’s Prince William and Kate Middleton began a three-day visit to India with a game of street cricket in Mumbai, the Princes of Wales’ most prominent overseas engagement since undergoing cancer treatment in 2024.
The nonpartisan Congressional Budget Office has estimated the policy will lead to 5.3 million more people being uninsured in the U.S. by 2034.
The American Cancer Society now recommends most men get their first PSA test when they turn 50. Black men and other men considered high risk should start screening at age 45.
Look at the promising data for Moderna and Merck’s experimental cancer vaccine and the research suggesting the shingles vaccine can delay dementia.
Revolution Medicines’ brand-new treatment brought in far higher sales than expected in its first few weeks on the market.
Yosemite has closed its cancer-focused second fund at $350 million, a serious jump from January’s first close at $200 million, investor Reed Jobs exclusively told Fortune.
Boehringer Ingelheim GmbH signed a licensing deal potentially worth more than $7 billion with China’s Sino Biopharmaceutical Limited and its subsidiaries for experimental cancer treatments.
The U.K. drugmaker benefited from strong sales of cancer drugs that offset the effect of patent expirations and lifted the group’s top line.
Moderna released full data on its closely watched cancer vaccine developed with Merck.


